SEC Filings

Form 424B5
ARRAY BIOPHARMA INC filed this Form 424B5 on 09/13/2017
Document Outline
Entire Document (541.5 KB)
Subdocument 1 - 424B5 - 424B5
Page 1 - Filed Pursuant to Rule 424(b)(5)
Page 2 - Table of contents
Page 3 - About this prospectus supplement
Page 4 - Prospectus supplement summary
Page 5 - Binimetinib and encorafenib
Page 6 - Pierre Fabre agreement
Page 7 - Ono agreement
Page 8 - COLUMBUS
Page 9 - COLUMBUS Part 2:
Page 10 - BEACON CRC
Page 11 - Bristol-Myers Squibb collaboration
Page 12 - SECOMBIT
Page 13 - ARRY-797
Page 14 - The offering
Page 15 - Risk factors
Page 16 - Because we do not intend to pay dividends, stockholders will benefit from an investment in our commo
Page 17 - We have broad discretion in the use of the net proceeds from this offering, and we may not use these
Page 18 - Forward-looking statements
Page 19 - Use of proceeds
Page 20 - Dilution
Page 21 - Price range of our common stock
Page 22 - Dividend policy
Page 23 - Material U.S. federal tax considerations to non-U.S. holders
Page 24 - If you are considering the purchase of our common stock, you should consult your own tax advisors co
Page 25 - Gain on disposition of common stock
Page 26 - Federal estate tax
Page 27 - THE PRECEDING DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY A
Page 28 - Underwriting
Page 29 - N/A
Page 30 - N/A
Page 31 - Selling restrictions
Page 32 - Notice to prospective investors in the United Kingdom
Page 33 - Notice to prospective investors in Switzerland
Page 34 - Notice to prospective investors in Hong Kong
Page 35 - Notice to prospective investors in China
Page 36 - Where you can find more information
Page 37 - http://www.arraybiopharma.com
Page 38 - PROSPECTUS
Page 39 - TABLE OF CONTENTS
Page 40 - ABOUT THIS PROSPECTUS
Page 41 - ABOUT ARRAY BIOPHARMA
Page 42 - USE OF PROCEEDS
Page 43 - Listing
Page 44 - N/A
Page 45 - Limitation of Liability of Directors
Page 46 - Staggered Board
Page 47 - Authorized but Unissued Shares
Page 48 - Dividends and Other Distributions
Page 49 - Conversion of Preferred Stock
Page 50 - Resignation and Removal of Depositary
Page 51 - N/A
Page 52 - Conversion or Exchange Rights
Page 53 - Discharge, Defeasance and Covenant Defeasance
Page 54 - Modification of the Indenture
Page 55 - N/A
Page 56 - Registered Global Securities and Book Entry System
Page 57 - N/A
Page 58 - Concerning the Trustee
Page 59 - Exercise of Warrants
Page 60 - Enforceability of Rights of Holders of Warrants
Page 61 - Issuance in Series
Page 62 - Street Name Holders
Page 63 - Special Considerations For Indirect Holders
Page 64 - Special Situations When A Global Security Will Be Terminated
Page 65 - PLAN OF DISTRIBUTION
Page 66 - Underwriters.
Page 67 - Passive Market Making.
Page 68 - INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
Page 69 - shares